Cilostazol improves lymphatic function by inducing proliferation and stabilization of lymphatic endothelial cells.
Identifieur interne : 006285 ( Ncbi/Merge ); précédent : 006284; suivant : 006286Cilostazol improves lymphatic function by inducing proliferation and stabilization of lymphatic endothelial cells.
Auteurs : Takayuki Kimura [Japon] ; Tatsuo S. Hamazaki [Japon] ; Makoto Sugaya [Japon] ; Shoji Fukuda [Japon] ; Techuan Chan [Japon] ; Miwa Tamura-Nakano [Japon] ; Shinichi Sato [Japon] ; Hitoshi Okochi [Japon]Source :
- Journal of dermatological science [ 1873-569X ] ; 2014.
Descripteurs français
- KwdFr :
- Animaux, Cellules cultivées, Cellules endothéliales (), Endothélium lymphatique (), Humains, Inhibiteurs de la phosphodiestérase-3 (pharmacologie), Inhibiteurs de la phosphodiestérase-3 (usage thérapeutique), Lymphangiogenèse (), Lymphoedème (traitement médicamenteux), Modèles animaux de maladie humaine, Mouvement cellulaire (), Prolifération cellulaire (), Souris, Souris transgéniques, Tétrazoles (pharmacologie), Tétrazoles (usage thérapeutique), Évaluation préclinique de médicament.
- MESH :
- pharmacologie : Inhibiteurs de la phosphodiestérase-3, Tétrazoles.
- traitement médicamenteux : Lymphoedème.
- usage thérapeutique : Inhibiteurs de la phosphodiestérase-3, Tétrazoles.
- Animaux, Cellules cultivées, Cellules endothéliales, Endothélium lymphatique, Humains, Lymphangiogenèse, Modèles animaux de maladie humaine, Mouvement cellulaire, Prolifération cellulaire, Souris, Souris transgéniques, Évaluation préclinique de médicament.
English descriptors
- KwdEn :
- Animals, Cell Movement (drug effects), Cell Proliferation (drug effects), Cells, Cultured, Disease Models, Animal, Drug Evaluation, Preclinical, Endothelial Cells (drug effects), Endothelium, Lymphatic (drug effects), Humans, Lymphangiogenesis (drug effects), Lymphedema (drug therapy), Mice, Mice, Transgenic, Phosphodiesterase 3 Inhibitors (pharmacology), Phosphodiesterase 3 Inhibitors (therapeutic use), Tetrazoles (pharmacology), Tetrazoles (therapeutic use).
- MESH :
- chemical , pharmacology : Phosphodiesterase 3 Inhibitors, Tetrazoles.
- drug effects : Cell Movement, Cell Proliferation, Endothelial Cells, Endothelium, Lymphatic, Lymphangiogenesis.
- drug therapy : Lymphedema.
- chemical , therapeutic use : Phosphodiesterase 3 Inhibitors, Tetrazoles.
- Animals, Cells, Cultured, Disease Models, Animal, Drug Evaluation, Preclinical, Humans, Mice, Mice, Transgenic.
Abstract
Cilostazol, an inhibitor of phosphodiesterase type III, is an antiplatelet agent and vasodilator. Some clinical reports have suggested that this drug can improve progressive and refractory lymphedema.
DOI: 10.1016/j.jdermsci.2014.01.001
PubMed: 24517869
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001678
- to stream PubMed, to step Curation: 001678
- to stream PubMed, to step Checkpoint: 001678
Links to Exploration step
pubmed:24517869Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cilostazol improves lymphatic function by inducing proliferation and stabilization of lymphatic endothelial cells.</title><author><name sortKey="Kimura, Takayuki" sort="Kimura, Takayuki" uniqKey="Kimura T" first="Takayuki" last="Kimura">Takayuki Kimura</name><affiliation wicri:level="4"><nlm:affiliation>Department of Regenerative Medicine, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan; Department of Dermatology, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Regenerative Medicine, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan; Department of Dermatology, Faculty of Medicine, The University of Tokyo, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region><settlement type="city">Tokyo</settlement></placeName><orgName type="university">Université de Tokyo</orgName></affiliation></author><author><name sortKey="Hamazaki, Tatsuo S" sort="Hamazaki, Tatsuo S" uniqKey="Hamazaki T" first="Tatsuo S" last="Hamazaki">Tatsuo S. Hamazaki</name><affiliation wicri:level="3"><nlm:affiliation>Department of Regenerative Medicine, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan. Electronic address: hamazaki@ri.ncgm.go.jp.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Regenerative Medicine, Research Institute, National Center for Global Health and Medicine, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Sugaya, Makoto" sort="Sugaya, Makoto" uniqKey="Sugaya M" first="Makoto" last="Sugaya">Makoto Sugaya</name><affiliation wicri:level="4"><nlm:affiliation>Department of Regenerative Medicine, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan; Department of Dermatology, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Regenerative Medicine, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan; Department of Dermatology, Faculty of Medicine, The University of Tokyo, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region><settlement type="city">Tokyo</settlement></placeName><orgName type="university">Université de Tokyo</orgName></affiliation></author><author><name sortKey="Fukuda, Shoji" sort="Fukuda, Shoji" uniqKey="Fukuda S" first="Shoji" last="Fukuda">Shoji Fukuda</name><affiliation wicri:level="3"><nlm:affiliation>Department of Cardiovascular Surgery, National Center for Global Health and Medicine, Tokyo, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Cardiovascular Surgery, National Center for Global Health and Medicine, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Chan, Techuan" sort="Chan, Techuan" uniqKey="Chan T" first="Techuan" last="Chan">Techuan Chan</name><affiliation wicri:level="3"><nlm:affiliation>Department of Regenerative Medicine, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Regenerative Medicine, Research Institute, National Center for Global Health and Medicine, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Tamura Nakano, Miwa" sort="Tamura Nakano, Miwa" uniqKey="Tamura Nakano M" first="Miwa" last="Tamura-Nakano">Miwa Tamura-Nakano</name><affiliation wicri:level="3"><nlm:affiliation>EM Support Unit, National Center for Global Health and Medicine, Tokyo, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>EM Support Unit, National Center for Global Health and Medicine, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Sato, Shinichi" sort="Sato, Shinichi" uniqKey="Sato S" first="Shinichi" last="Sato">Shinichi Sato</name><affiliation wicri:level="4"><nlm:affiliation>Department of Dermatology, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Dermatology, Faculty of Medicine, The University of Tokyo, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region><settlement type="city">Tokyo</settlement></placeName><orgName type="university">Université de Tokyo</orgName></affiliation></author><author><name sortKey="Okochi, Hitoshi" sort="Okochi, Hitoshi" uniqKey="Okochi H" first="Hitoshi" last="Okochi">Hitoshi Okochi</name><affiliation wicri:level="3"><nlm:affiliation>Department of Regenerative Medicine, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Regenerative Medicine, Research Institute, National Center for Global Health and Medicine, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24517869</idno><idno type="pmid">24517869</idno><idno type="doi">10.1016/j.jdermsci.2014.01.001</idno><idno type="wicri:Area/PubMed/Corpus">001678</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001678</idno><idno type="wicri:Area/PubMed/Curation">001678</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001678</idno><idno type="wicri:Area/PubMed/Checkpoint">001678</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001678</idno><idno type="wicri:Area/Ncbi/Merge">006285</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Cilostazol improves lymphatic function by inducing proliferation and stabilization of lymphatic endothelial cells.</title><author><name sortKey="Kimura, Takayuki" sort="Kimura, Takayuki" uniqKey="Kimura T" first="Takayuki" last="Kimura">Takayuki Kimura</name><affiliation wicri:level="4"><nlm:affiliation>Department of Regenerative Medicine, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan; Department of Dermatology, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Regenerative Medicine, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan; Department of Dermatology, Faculty of Medicine, The University of Tokyo, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region><settlement type="city">Tokyo</settlement></placeName><orgName type="university">Université de Tokyo</orgName></affiliation></author><author><name sortKey="Hamazaki, Tatsuo S" sort="Hamazaki, Tatsuo S" uniqKey="Hamazaki T" first="Tatsuo S" last="Hamazaki">Tatsuo S. Hamazaki</name><affiliation wicri:level="3"><nlm:affiliation>Department of Regenerative Medicine, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan. Electronic address: hamazaki@ri.ncgm.go.jp.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Regenerative Medicine, Research Institute, National Center for Global Health and Medicine, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Sugaya, Makoto" sort="Sugaya, Makoto" uniqKey="Sugaya M" first="Makoto" last="Sugaya">Makoto Sugaya</name><affiliation wicri:level="4"><nlm:affiliation>Department of Regenerative Medicine, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan; Department of Dermatology, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Regenerative Medicine, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan; Department of Dermatology, Faculty of Medicine, The University of Tokyo, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region><settlement type="city">Tokyo</settlement></placeName><orgName type="university">Université de Tokyo</orgName></affiliation></author><author><name sortKey="Fukuda, Shoji" sort="Fukuda, Shoji" uniqKey="Fukuda S" first="Shoji" last="Fukuda">Shoji Fukuda</name><affiliation wicri:level="3"><nlm:affiliation>Department of Cardiovascular Surgery, National Center for Global Health and Medicine, Tokyo, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Cardiovascular Surgery, National Center for Global Health and Medicine, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Chan, Techuan" sort="Chan, Techuan" uniqKey="Chan T" first="Techuan" last="Chan">Techuan Chan</name><affiliation wicri:level="3"><nlm:affiliation>Department of Regenerative Medicine, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Regenerative Medicine, Research Institute, National Center for Global Health and Medicine, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Tamura Nakano, Miwa" sort="Tamura Nakano, Miwa" uniqKey="Tamura Nakano M" first="Miwa" last="Tamura-Nakano">Miwa Tamura-Nakano</name><affiliation wicri:level="3"><nlm:affiliation>EM Support Unit, National Center for Global Health and Medicine, Tokyo, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>EM Support Unit, National Center for Global Health and Medicine, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Sato, Shinichi" sort="Sato, Shinichi" uniqKey="Sato S" first="Shinichi" last="Sato">Shinichi Sato</name><affiliation wicri:level="4"><nlm:affiliation>Department of Dermatology, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Dermatology, Faculty of Medicine, The University of Tokyo, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region><settlement type="city">Tokyo</settlement></placeName><orgName type="university">Université de Tokyo</orgName></affiliation></author><author><name sortKey="Okochi, Hitoshi" sort="Okochi, Hitoshi" uniqKey="Okochi H" first="Hitoshi" last="Okochi">Hitoshi Okochi</name><affiliation wicri:level="3"><nlm:affiliation>Department of Regenerative Medicine, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Regenerative Medicine, Research Institute, National Center for Global Health and Medicine, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author></analytic><series><title level="j">Journal of dermatological science</title><idno type="eISSN">1873-569X</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Cell Movement (drug effects)</term><term>Cell Proliferation (drug effects)</term><term>Cells, Cultured</term><term>Disease Models, Animal</term><term>Drug Evaluation, Preclinical</term><term>Endothelial Cells (drug effects)</term><term>Endothelium, Lymphatic (drug effects)</term><term>Humans</term><term>Lymphangiogenesis (drug effects)</term><term>Lymphedema (drug therapy)</term><term>Mice</term><term>Mice, Transgenic</term><term>Phosphodiesterase 3 Inhibitors (pharmacology)</term><term>Phosphodiesterase 3 Inhibitors (therapeutic use)</term><term>Tetrazoles (pharmacology)</term><term>Tetrazoles (therapeutic use)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Cellules cultivées</term><term>Cellules endothéliales ()</term><term>Endothélium lymphatique ()</term><term>Humains</term><term>Inhibiteurs de la phosphodiestérase-3 (pharmacologie)</term><term>Inhibiteurs de la phosphodiestérase-3 (usage thérapeutique)</term><term>Lymphangiogenèse ()</term><term>Lymphoedème (traitement médicamenteux)</term><term>Modèles animaux de maladie humaine</term><term>Mouvement cellulaire ()</term><term>Prolifération cellulaire ()</term><term>Souris</term><term>Souris transgéniques</term><term>Tétrazoles (pharmacologie)</term><term>Tétrazoles (usage thérapeutique)</term><term>Évaluation préclinique de médicament</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Phosphodiesterase 3 Inhibitors</term><term>Tetrazoles</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Cell Movement</term><term>Cell Proliferation</term><term>Endothelial Cells</term><term>Endothelium, Lymphatic</term><term>Lymphangiogenesis</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Lymphedema</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Inhibiteurs de la phosphodiestérase-3</term><term>Tétrazoles</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Phosphodiesterase 3 Inhibitors</term><term>Tetrazoles</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Lymphoedème</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Inhibiteurs de la phosphodiestérase-3</term><term>Tétrazoles</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Cells, Cultured</term><term>Disease Models, Animal</term><term>Drug Evaluation, Preclinical</term><term>Humans</term><term>Mice</term><term>Mice, Transgenic</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Cellules cultivées</term><term>Cellules endothéliales</term><term>Endothélium lymphatique</term><term>Humains</term><term>Lymphangiogenèse</term><term>Modèles animaux de maladie humaine</term><term>Mouvement cellulaire</term><term>Prolifération cellulaire</term><term>Souris</term><term>Souris transgéniques</term><term>Évaluation préclinique de médicament</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Cilostazol, an inhibitor of phosphodiesterase type III, is an antiplatelet agent and vasodilator. Some clinical reports have suggested that this drug can improve progressive and refractory lymphedema.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24517869</PMID><DateCreated><Year>2014</Year><Month>04</Month><Day>02</Day></DateCreated><DateCompleted><Year>2014</Year><Month>12</Month><Day>09</Day></DateCompleted><DateRevised><Year>2014</Year><Month>04</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-569X</ISSN><JournalIssue CitedMedium="Internet"><Volume>74</Volume><Issue>2</Issue><PubDate><Year>2014</Year><Month>May</Month></PubDate></JournalIssue><Title>Journal of dermatological science</Title><ISOAbbreviation>J. Dermatol. Sci.</ISOAbbreviation></Journal><ArticleTitle>Cilostazol improves lymphatic function by inducing proliferation and stabilization of lymphatic endothelial cells.</ArticleTitle><Pagination><MedlinePgn>150-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jdermsci.2014.01.001</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0923-1811(14)00006-1</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Cilostazol, an inhibitor of phosphodiesterase type III, is an antiplatelet agent and vasodilator. Some clinical reports have suggested that this drug can improve progressive and refractory lymphedema.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">In this study, we investigated whether cilostazol has the potential to proliferate lymphatic vessels and to improve lymphatic function using human lymphatic endothelial cells (LECs) and mouse lymphedema models.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Human LECs were counted at several time points while they were cultured in the presence of cilostazol and/or protein kinase A inhibitor. After receiving a diet including 0.1% cilostazol or control diet, skin tissue and lymphatic function of k-cyclin transgenic (kCYC(+/-)) mice, which have pernicious lymphatic dysfunction, was analyzed. A different lymphedema model was generated in wild type mice by excising circumferential tail skin to remove the superficial lymphatics. After oral administration of cilostazol, tail lymphedema was examined in this mouse model.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Proliferation of LECs was promoted in a dose-dependent manner, which was partially inhibited by a protein kinase A inhibitor. Lymphatic vessel count increased in the cilostazol-treated kCYC(+/-) mice over that in the non-treated mice. Lymph flow improved in cilostazol-fed kCYC(+/-) mice as assessed by subcutaneous injection of Evans blue dye into the footpad. Oral administration of cilostazol also decreased lymphedema in a tail of wild type mice.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Cilostazol promoted growth of human LECs and improved lymph flow and lymphedema in two different mouse lymphedema models. These results suggest that cilostazol would be a promising agent for the treatment of lymphedema.</AbstractText><CopyrightInformation>Copyright © 2014 Japanese Society for Investigative Dermatology. Published by Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kimura</LastName><ForeName>Takayuki</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Regenerative Medicine, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan; Department of Dermatology, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamazaki</LastName><ForeName>Tatsuo S</ForeName><Initials>TS</Initials><AffiliationInfo><Affiliation>Department of Regenerative Medicine, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan. Electronic address: hamazaki@ri.ncgm.go.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sugaya</LastName><ForeName>Makoto</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Regenerative Medicine, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan; Department of Dermatology, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fukuda</LastName><ForeName>Shoji</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, National Center for Global Health and Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Techuan</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Regenerative Medicine, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tamura-Nakano</LastName><ForeName>Miwa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>EM Support Unit, National Center for Global Health and Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sato</LastName><ForeName>Shinichi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okochi</LastName><ForeName>Hitoshi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Regenerative Medicine, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>01</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Dermatol Sci</MedlineTA><NlmUniqueID>9011485</NlmUniqueID><ISSNLinking>0923-1811</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058987">Phosphodiesterase 3 Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013777">Tetrazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>N7Z035406B</RegistryNumber><NameOfSubstance UI="C045645">cilostazol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004353" MajorTopicYN="N">Drug Evaluation, Preclinical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042783" MajorTopicYN="N">Endothelial Cells</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004729" MajorTopicYN="N">Endothelium, Lymphatic</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042583" MajorTopicYN="N">Lymphangiogenesis</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008209" MajorTopicYN="N">Lymphedema</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058987" MajorTopicYN="N">Phosphodiesterase 3 Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013777" MajorTopicYN="N">Tetrazoles</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cilostazol</Keyword><Keyword MajorTopicYN="N">Lymphatic endothelial cells</Keyword><Keyword MajorTopicYN="N">Lymphedema</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>09</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2013</Year><Month>12</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>01</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>2</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>2</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24517869</ArticleId><ArticleId IdType="pii">S0923-1811(14)00006-1</ArticleId><ArticleId IdType="doi">10.1016/j.jdermsci.2014.01.001</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Japon</li></country><region><li>Région de Kantō</li></region><settlement><li>Tokyo</li></settlement><orgName><li>Université de Tokyo</li></orgName></list><tree><country name="Japon"><region name="Région de Kantō"><name sortKey="Kimura, Takayuki" sort="Kimura, Takayuki" uniqKey="Kimura T" first="Takayuki" last="Kimura">Takayuki Kimura</name></region><name sortKey="Chan, Techuan" sort="Chan, Techuan" uniqKey="Chan T" first="Techuan" last="Chan">Techuan Chan</name><name sortKey="Fukuda, Shoji" sort="Fukuda, Shoji" uniqKey="Fukuda S" first="Shoji" last="Fukuda">Shoji Fukuda</name><name sortKey="Hamazaki, Tatsuo S" sort="Hamazaki, Tatsuo S" uniqKey="Hamazaki T" first="Tatsuo S" last="Hamazaki">Tatsuo S. Hamazaki</name><name sortKey="Okochi, Hitoshi" sort="Okochi, Hitoshi" uniqKey="Okochi H" first="Hitoshi" last="Okochi">Hitoshi Okochi</name><name sortKey="Sato, Shinichi" sort="Sato, Shinichi" uniqKey="Sato S" first="Shinichi" last="Sato">Shinichi Sato</name><name sortKey="Sugaya, Makoto" sort="Sugaya, Makoto" uniqKey="Sugaya M" first="Makoto" last="Sugaya">Makoto Sugaya</name><name sortKey="Tamura Nakano, Miwa" sort="Tamura Nakano, Miwa" uniqKey="Tamura Nakano M" first="Miwa" last="Tamura-Nakano">Miwa Tamura-Nakano</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 006285 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 006285 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:24517869
|texte= Cilostazol improves lymphatic function by inducing proliferation and stabilization of lymphatic endothelial cells.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:24517869" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |